News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pipex Pharmaceuticals (PPXP)' Oral Flupirtine Receives IRB Approval to Initiate Phase II Clinical Trial for Fibromyalgia



10/7/2008 9:02:23 AM

ANN ARBOR, Mich., Oct. 7, 2008 (GLOBE NEWSWIRE) -- Pipex Pharmaceuticals, Inc. (AMEX:PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous system and autoimmune diseases, today announced that its double-blind, randomized, placebo-controlled phase II clinical trial of oral flupirtine for the treatment of fibromyalgia has received ethics committee approval to initiate the clinical trial.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES